Join Carisma Therapeutics, Pfizer, Gilead Sciences, Regeneron Pharmaceuticals, MiNA Therapeutics, Pionyr Immunotherapeutics and more in the race to remove tumor microenvironment barriers to therapeutic success by unlocking novel targets and harnessing myeloid cells in mono and combination therapies.